News Feb 29, 2016
PeptiMimesis has announced the inception and launch of its activities to develop a novel class of therapeutic peptides using a breakthrough technology from the University of Strasbourg and INSERM (French Institute of Health and Medical Research). PeptiMimesis will now apply this cutting edge approach to a first set of 60 targets including the most promising in the chosen therapeutic areas.
Over the past 2 years, the tech transfer office SATT Conectus supported the team to develop the technology up to the proof of concept. PeptiMimesis was founded by three academic researchers, each having more than 15 years of experience in the field of transmembrane peptides, and Domain Therapeutics, a drug discovery company with a long and successful track record in targeting membrane receptors.
“This new venture highlights the quality of the incubation phase conducted by SATT Conectus and the high standard of research carried out by the University of Strasbourg and INSERM,” said Pascal Neuville, CEO of Domain Therapeutics.
“The creation of PeptiMimesis is the culmination of many years of work developing our technology,” said Dr Dominique Bagnard, founder. “With my two long-standing collaborators and co-founders, Dr Gérard Crémel and Dr Pierre Hubert, we are pleased to partner with Domain Therapeutics to develop our research and launch PeptiMimesis on the road to success.”
“Domain Therapeutics is ideally positioned to help bridge the gap between a breakthrough technology developed by a nascent company and the expectations of pharma partners. We strongly believe that our expertise will allow PeptiMimesis’ platform to deliver promising and valuable peptides to answer patient needs,” said Pascal Neuville.